Search
Nirmatrelvir
go.drugbank.com/drugs/DB16691ApprovedInvestigational[L33359] Nirmatrelvir is advantageous in that it can be prescribed to patients before they require hospitalization, while [PF-07304814] requires intravenous administration in hospital. … [L46921] Paxlovid was approved for use in Canada in January 2022 for the treatment of adult patients with mild-moderate COVID-19 [L39544] and later granted conditional marketing authorization by the European
Remimazolam
go.drugbank.com/drugs/DB12404ApprovedInvestigationalRemimazolam is an ultra short-acting benzodiazepine used in the induction and maintenance of sedation during short (<30 minute) procedures. … [A214857] These "soft drugs" are useful in the context of surgical procedures, wherein a rapid onset/offset is desirable, enabling anesthesiologists to manipulate drug concentrations as needed.
Rilzabrutinib
go.drugbank.com/drugs/DB17709ApprovedInvestigationalRilzabrutinib is thought to work by dual mechanisms of action in ITP: It attenuates macrophage (Fcγ receptor)-mediated platelet destruction and reduces the production of pathogenic autoantibodies. … [L53743] ITP is an autoimmune disorder characterized by low platelet count.
Cupric oxide
go.drugbank.com/drugs/DB11134ApprovedCopper(II) oxide nanoparticles (NPCuO) have industrial applications as antimicrobial agents in textiles and paints, and catalysts in organic synthesis [A32656]. … Cupric oxide is used as a precursor in many copper-containing products such as wood preservatives and ceramics.
Mixtures: Virt-Pn, Virt-PNZYC300
go.drugbank.com/drugs/DB04986InvestigationalIt is designed as a vaccine, intended to increase immune system sensitivity to CYP1B1, an enzyme highly prevalent in tumor cells. … ZYC300 is a plasmid DNA of CYP1B1 encapsulated in biodegradable poly-DL-lactide-coglycolide microparticles.
Desvenlafaxine
go.drugbank.com/drugs/DB06700ApprovedInvestigational[L6016,A261271] MDD is a highly prevalent psychiatric disorder, with a lifetime prevalence estimate of 16% in the US alone and 12.8% in Europe. … [A261266,A261266] It was approved by the FDA in 2008 for the treatment of adults with major depressive disorder (MDD).
Enoximone
go.drugbank.com/drugs/DB04880ApprovedInvestigationalWithdrawnIt is used in patients with congestive heart failure. Trials were halted in the U.S., but the drug is used in various countries. … Enoximone is a selective phosphodiesterase inhibitor with vasodilating and positive inotropic activity that does not cause changes in myocardial oxygen consumption.
Categories: Compounds used in a research, industrial, or household settingCTS-21166
go.drugbank.com/drugs/DB06073Investigational, and oral availability; all of these have met the requirements of an ideal oral drug candidate. … In 2008, CoMentis revealed this small compound as a transition-state analog inhibitor (structure is currently undisclosed) with excellent properties in brain penetration, selectivity, metabolic stability
Emapalumab
go.drugbank.com/drugs/DB14724ApprovedInvestigationalEmapalumab, also known as NI-0501, is a fully human monoclonal antibody that targets interferon gamma. … Emapalumab development was sponsored by NovImmune SA, further developed by Sobi and FDA approved on November 20, 2018.
Deutetrabenazine
go.drugbank.com/drugs/DB12161ApprovedInvestigationalIn clinical trials of patients with HD, 12 weeks of treatment of deutetrabenazine resulted in overall improvement in mean total maximal chorea scores and motor signs than placebo [A32046]. … It was approved by FDA in April 2017 and is marketed under the trade name Austedo as oral tablets.